These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 37730274

  • 21. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells.
    Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA.
    Cell Rep Med; 2022 Mar 15; 3(3):100554. PubMed ID: 35492873
    [Abstract] [Full Text] [Related]

  • 22. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E, Garmendia I, Lozano T, Serrano D, Senent Y, Redrado M, Villalba M, De Andrea CE, Exposito F, Ajona D, Ortiz-Espinosa S, Remirez A, Bertolo C, Sainz C, Garcia-Pedrero J, Pio R, Lasarte J, Agorreta J, Montuenga LM, Calvo A.
    J Immunother Cancer; 2021 Mar 15; 9(3):. PubMed ID: 33658304
    [Abstract] [Full Text] [Related]

  • 23. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, Zhang J, Yan Y, Zhou P, Chu Q, Wu K.
    J Hematol Oncol; 2022 Oct 08; 15(1):142. PubMed ID: 36209176
    [Abstract] [Full Text] [Related]

  • 24. PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer.
    Kadam P, Sharma S.
    Vaccines (Basel); 2020 Jun 18; 8(2):. PubMed ID: 32570793
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K, Park S, Park SY, Kim G, Park SM, Cho JW, Kim DH, Park YM, Koh YW, Kim HR, Ha SJ, Lee I.
    Genome Med; 2020 Feb 28; 12(1):22. PubMed ID: 32111241
    [Abstract] [Full Text] [Related]

  • 31. CCL21 Programs Immune Activity in Tumor Microenvironment.
    Sharma S, Kadam P, Dubinett S.
    Adv Exp Med Biol; 2020 Feb 28; 1231():67-78. PubMed ID: 32060847
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
    Zhang H, Huang H, Wu S, He X, Chen J, Zheng X, Chen L, Wang Z.
    Med Oncol; 2023 Aug 31; 40(10):285. PubMed ID: 37653265
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
    Fang C, Zhang C, Zhao WQ, Hu WW, Wu J, Ji M.
    BMC Med Genomics; 2019 Oct 16; 12(1):136. PubMed ID: 31619231
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.
    Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, Lee JM.
    J Transl Med; 2008 Jul 22; 6():38. PubMed ID: 18644162
    [Abstract] [Full Text] [Related]

  • 38. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H, Park S, Han KY, Lee N, Kim H, Jung HA, Sun JM, Ahn JS, Ahn MJ, Lee SH, Park WY.
    J Immunother Cancer; 2023 Feb 22; 11(2):. PubMed ID: 36787939
    [Abstract] [Full Text] [Related]

  • 39. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
    Chen Q, Yin H, Pu N, Zhang J, Zhao G, Lou W, Wu W.
    Cancer Sci; 2021 Nov 22; 112(11):4457-4469. PubMed ID: 34402138
    [Abstract] [Full Text] [Related]

  • 40. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A, Feilotter H, Hopman W, Fung AS, Robinson A.
    Cancer Treat Res Commun; 2021 Nov 22; 27():100330. PubMed ID: 33581492
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.